Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Mesalazine impurity 2 is a known impurity associated with the anti-inflammatory drug Mesalazine. This compound is utilized primarily in analytical chemistry for quality control and characterization of Mesalazine formulations. Its presence can impact the efficacy and safety of pharmaceutical products, making it important for drug development and regulatory compliance studies. -
Drug Impurity
Cholic acid impurity 1 is a chemical impurity associated with cholic acid, a primary bile acid involved in the digestion and absorption of fats. This compound is crucial for quality control and characterization in pharmaceutical research, particularly in the context of drug formulation and assessment of purity. Cholic acid impurity 1 supports investigations into the safety and efficacy of compounds that include cholic acid within their formulations. -
Drug Impurity
Methyl phenyl sulfone is a sulfone compound often identified as a drug impurity in pharmaceutical formulations. It can affect drug stability and bioavailability, making it significant in analytical chemistry and quality control. Researchers utilize this reagent to assess purity in drug synthesis and to evaluate the potential impact of impurities on pharmacological profiles. -
Drug Impurity
Tofacitinib impurity 3 is a known impurity of the JAK1/3 inhibitor Tofacitinib. It is primarily utilized for assessing the purity and quality of Tofacitinib in pharmaceutical formulations. This impurity serves as a valuable reference standard in the development and analysis of therapeutic agents targeting immune-mediated disorders. -
Drug Impurity
Metformin impurity 1 is a known impurity associated with the antidiabetic agent Metformin. This compound is important for quality control and regulatory compliance in pharmaceutical research, particularly in the analysis of drug formulations. Its presence and characterization are critical for ensuring the purity and efficacy of Metformin-containing products. -
Drug Impurity
Nintedanib impurity 4 is a known impurity of the multi-kinase inhibitor, Nintedanib, which primarily targets VEGFR, FGFR, and PDGFR pathways. This compound serves as a reference standard for the evaluation of drug purity and stability in pharmaceutical development. It is essential for researchers investigating the pharmacokinetics, safety, and regulatory compliance of Nintedanib in various biological assays and analytical methods. -
Drug Impurity
Apixaban impurity 41 is a known impurity associated with Apixaban, a direct factor Xa inhibitor. This compound is utilized in the pharmaceutical research setting to assess the purity and quality of Apixaban formulations. Its characterization is crucial for regulatory compliance and ensuring the therapeutic efficacy of Apixaban in clinical applications. -
Drug Impurity
Olanzapine impurity 2 hydrochloride is a known impurity of the antipsychotic compound, Olanzapine hydrochloride. This reagent plays a critical role in drug quality control and formulation research, facilitating the assessment of purity and stability in pharmaceutical preparations. Its examination is essential for regulatory compliance and the development of safer therapeutic agents. -
Drug Impurity
Methyl 2-tert-Butyloxycarbonylaminoacrylate is characterized as a drug impurity that may emerge during the synthesis of pharmaceutical compounds. This compound serves as a key reference standard in analytical chemistry, aiding in the identification and quantification of related substances in drug development. Its presence is relevant for ensuring the purity and safety profiles of therapeutic agents. -
Drug Impurity
Apixaban impurity 13 is a chemical impurity associated with the anticoagulant drug Apixaban. This compound is critical for analytical and quality control studies in pharmaceutical research, particularly in assessing the purity of Apixaban formulations. The presence of such impurities can affect the pharmacological profile and safety of the final product, making it essential for ensuring compliance with regulatory standards in drug development. -
Drug Impurity
N,N-Dibenzylacetamide is a drug impurity commonly encountered in pharmaceutical formulations. Its presence can influence the pharmacokinetics and efficacy of active pharmaceutical ingredients. This compound is of particular interest for analytical research focused on drug quality assessment and regulatory compliance. Understanding and analyzing impurities such as N,N-Dibenzylacetamide is crucial for ensuring the safety and effectiveness of drug products. -
Drug Impurity
Leflunomide impurity 7 is a known impurity associated with Leflunomide, an immunosuppressive agent. This compound is primarily utilized in research for quality control and characterization of Leflunomide formulations. It provides insights into the synthesis process and potential impacts on drug efficacy and safety profiles during pharmaceutical development. -
Drug Impurity
Tolterodine impurity 1 is a chemical impurity associated with Tolterodine, a pharmaceutical agent primarily used for the management of overactive bladder. This impurity may be utilized in research applications focused on drug formulation, stability analysis, and quality control to ensure the purity and safety of pharmaceutical products. Characterization of this impurity can aid in the understanding of Tolterodine metabolism and its potential effects on pharmacokinetics. -
Drug Impurity
Ketoprofen impurity 2 is a chemical impurity associated with Ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID). This impurity can be utilized in the study of drug purity and stability, aiding in the assessment of pharmaceutical quality control. Its characterization is essential for compliance with regulatory standards in pharmaceutical development and manufacturing. -
Drug Impurity
Metformin impurity 12, also known as N2,N2-Dimethylmelamine, is a recognized impurity associated with the synthesis of Metformin. This compound is of significant interest in the study of pharmaceutical quality and safety, aiding in the assessment of drug formulations. It serves as a reference standard for analytical techniques, providing critical data for ensuring the purity and efficacy of Metformin-based medications. -
Drug Impurity
Sacubitrilat impurity 32 is an identified impurity associated with the therapeutic agent Sacubitrilat. Its presence in pharmaceutical formulations may have implications for drug quality, safety, and efficacy. This reagent is utilized in the analysis and characterization of Sacubitrilat to ensure compliance with regulatory standards and to support research in drug metabolism and pharmacokinetics. -
Drug Impurity
Edoxaban impurity 11 is a known impurity associated with the anticoagulant Edoxaban. This compound is utilized in analytical chemistry and pharmacological research to assess the purity and quality of Edoxaban formulations. Its presence can impact the safety and efficacy of drug products, making it vital for regulatory compliance and stability studies. -
Drug Impurity
Ibuprofen impurity 6, also known as p-Butylhydratropic Acid, is a recognized impurity associated with Ibuprofen. It serves as an important analytical reference for quality control and characterization in pharmaceutical formulations. This compound aids in the identification and quantification of impurities during drug development and testing processes, ensuring compliance with regulatory standards in the pharmaceutical industry. -
Drug Impurity
Rivaroxaban impurity 1 is a known drug impurity related to Rivaroxaban, a selective inhibitor of factor Xa. This impurity is critical for analytical chemistry applications, particularly in the quality control and characterization of Rivaroxaban in pharmaceutical formulations. It serves as a reference standard for assessing the purity and stability of Rivaroxaban compounds in research and development settings. -
Drug Impurity
Oxcarbazepine impurity 2 is a recognized impurity associated with the anticonvulsant drug oxcarbazepine. Its main application lies in the assessment of drug purity and quality control during the pharmaceutical development process. Understanding and characterizing this impurity is crucial for ensuring the safety and efficacy of pharmaceutical formulations containing oxcarbazepine. -
Drug Impurity
3-Methyl-2H-indazol-6-amine is a chemical compound commonly identified as a drug impurity. Its presence in pharmaceutical formulations may influence the safety and efficacy of active compounds. Research applications include the assessment of pharmaceutical quality and the study of impurity effects on drug performance and stability. -
Drug Impurity
2-(2,2,2-Trifluoroethoxy)pyridin-3-amine is identified as a drug impurity with a potential impact on drug development and safety assessments. It serves as a valuable reference standard for analytical methods such as HPLC and LC-MS. Researchers may utilize this compound to better understand the metabolic pathways and toxicity profiles of related pharmaceutical agents. -
Drug Impurity
Rivaroxaban impurity 6 is a known impurity related to the anticoagulant Rivaroxaban, acting primarily as a drug impurity marker. This compound is crucial for analytical applications, particularly in the validation and quality control of pharmaceutical formulations containing Rivaroxaban. Its presence and quantification are essential for ensuring compliance with regulatory standards in drug development and manufacturing processes. -
Drug Impurity
Cinacase impurity 12 is a chemical impurity associated with the synthesis of Cinacase. This compound is relevant in the pharmaceutical industry for quality control and assessment of drug formulations. It aids in understanding the impurity profile of Cinacase, which is essential for ensuring the safety and efficacy of the final pharmaceutical product. -
Drug Impurity
Ticagrelor impurity 11 is a known impurity associated with Ticagrelor, a potent P2Y12 adenosine diphosphate receptor antagonist. This compound may be utilized in analytical studies to assess the purity of Ticagrelor formulations, contributing to quality control and regulatory compliance in pharmaceuticals. Its characterization can provide insights into the stability and degradation pathways of Ticagrelor, aiding researchers in understanding its chemical behavior and efficacy. -
Drug Impurity
Remimazolam impurity 4 is a known impurity associated with the anesthetic compound Remimazolam. It is characterized by its potential effects on the pharmacological profile of the parent compound. This impurity is significant for research applications related to drug formulation, stability testing, and safety assessment in pharmacokinetic studies. Understanding its properties can help ensure the quality and efficacy of anesthetic products. -
Drug Impurity
Favipiravir impurity 5 is a characterized impurity of the antiviral compound Favipiravir, known for its activity against various RNA viruses. This reagent plays a critical role in the assessment of drug quality and stability during pharmaceutical development. Favipiravir impurity 5 is essential for analytical studies aimed at understanding the implications of impurities on drug efficacy and safety. -
Drug Impurity
Tofacitinib impurity 4 is a chemical impurity related to Tofacitinib, an oral Janus kinase (JAK) inhibitor. This impurity may be useful for characterization studies, quality control, and impurity profiling in the development and manufacturing of Tofacitinib. It provides valuable insights into the pharmaceutical formulation and stability of the drug, assisting researchers in ensuring safety and efficacy standards. -
Drug Impurity
Afatinib impurity 17 is a known impurity associated with Afatinib, a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinases. This compound is primarily used in the characterization and quality control of pharmaceutical formulations containing Afatinib. Its analysis is crucial for ensuring compliance with regulatory standards and assessing the purity of drug substances in research and development. -
Drug Impurity
Suvorexant impurity 2 is a known impurity of the sleep aid Suvorexant, functioning as a competitive antagonist of orexin receptors. This compound is primarily utilized in chemical analysis and quality control of Suvorexant formulations, as well as in the study of drug metabolism and stability. Its presence is critical for ensuring the purity and efficacy of pharmaceutical products containing Suvorexant. -
Drug Impurity
(S)-Cinacalcet hydrochloride is a drug impurity associated with cinacalcet, a calcimimetic agent that targets the calcium-sensing receptor. This compound is primarily utilized in research to study drug metabolism, stability, and safety profiles of cinacalcet formulations. Its analysis is critical for ensuring the quality and regulatory compliance of pharmaceutical developments. -
Drug Impurity
Rivastigmine impurity 12 (m-Methoxyacetophenone) is a known impurity associated with Rivastigmine, an acetylcholinesterase inhibitor used in the treatment of Alzheimer's disease. This compound serves as a valuable reference material for analytical chemistry applications, particularly in the development and validation of analytical methods for drug quality control. Its characterization contributes to ensuring the safety and efficacy of pharmaceutical formulations containing Rivastigmine. -
Drug Impurity
Acetazolamide impurity 2 (NSC 231656) is characterized as a minor impurity of the carbonic anhydrase inhibitor, Acetazolamide. This compound is relevant for quality control and assurance in pharmaceutical formulations, particularly for studies assessing the purity and stability of Acetazolamide. Its identification and quantification may facilitate research on drug efficacy and safety in various therapeutic applications. -
Drug Impurity
Pregabalin impurity 3 is a recognized impurity associated with the drug Pregabalin, which primarily targets voltage-gated calcium channels. This compound may play a role in understanding the metabolic pathways and degradation processes of Pregabalin. Research applications of Pregabalin impurity 3 include method development for impurity analysis in pharmaceuticals and exploring potential interactions that could affect drug safety and efficacy. -
Drug Impurity
Rivaroxaban impurity 70 is a chemical impurity associated with the anticoagulant Rivaroxaban. This compound is primarily used in pharmaceutical research to investigate the safety, efficacy, and quality of Rivaroxaban formulations. Its characterization is essential for compliance with regulatory standards and the development of robust drug manufacturing processes. -
Drug Impurity
Pramipexole impurity 9 is a chemical impurity associated with Pramipexole, a dopamine D2 receptor agonist used in the treatment of Parkinson's disease and restless legs syndrome. This impurity is relevant for analytical studies and quality control in pharmaceutical development, particularly in assessing the purity of Pramipexole formulations. Its characterization aids in understanding the stability and metabolism of the primary compound, ensuring safety and efficacy in therapeutic applications. -
Drug Impurity
Glycopyrronium impurity 6 is a chemical impurity associated with Glycopyrronium, a medication utilized for its anticholinergic properties. This impurity is relevant for quality control and analytical chemistry applications in pharmaceutical development. Its characterization is essential for ensuring the purity and efficacy of Glycopyrronium formulations in drug research and regulatory compliance. -
Drug Impurity
Ramipril Impurity 10 is a byproduct of Ramipril, a well-known angiotensin-converting enzyme (ACE) inhibitor. This impurity serves as a critical reference standard in pharmaceutical quality control and formulation development. Its characterization is essential for ensuring the integrity and safety of Ramipril-containing formulations in various research applications. -
Drug Impurity
Norepinephrine tartrate impurity 33 is an identified impurity associated with the adrenergic neurotransmitter norepinephrine tartrate. This compound may be utilized in pharmaceutical development and quality control assays to assess the purity of norepinephrine formulations. Its presence and characterization are crucial for ensuring compliance with regulatory standards and maintaining the integrity of therapeutic preparations. -
Drug Impurity
Rivaroxaban impurity 71, also known as N-Methylphthalimide, is a chemical impurity associated with Rivaroxaban synthesis. It serves as a reference standard for quality control and analytical studies in pharmaceutical development. This compound is critical for ensuring the purity and safety of Rivaroxaban formulations, facilitating research on drug efficacy and stability. -
Drug Impurity
Ribociclib impurity 5 is a specific impurity associated with Ribociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). This compound serves important roles in the quality control and characterization of ribociclib formulations. Its presence may impact drug efficacy and safety profiles, making it relevant for pharmacological and toxicological studies. Researchers can utilize Ribociclib impurity 5 to ensure analytical rigor in drug development and formulation testing. -
Drug Impurity
Ribociclib impurity 3 is a known impurity associated with Ribociclib, an FDA-approved cyclin-dependent kinase (CDK) inhibitor. This compound serves as a valuable reference material for the characterization and quality control of Ribociclib formulations. It is essential for analytical research and development, particularly in pharmacokinetic studies and stability assessments of CDK inhibitors. -
Drug Impurity
(1S,2R)-2-Fluorocyclopropan-1-amine hydrochloride is a chemical compound often encountered as a drug impurity. Its primary target is related to its role in the synthesis and analysis of various pharmaceutical formulations. This reagent is utilized in research applications focused on evaluating drug purity, stability, and potential biological impacts of impurities in pharmacological studies. -
Drug Impurity
Naproxen Impurity 4 is a characterized impurity associated with the nonsteroidal anti-inflammatory drug (NSAID) Naproxen. This compound is significant for quality control and analytical assessments in pharmaceutical research, providing insights into the purity and stability of Naproxen formulations. Its analysis can aid in understanding the compound's safety profile and potential effects on efficacy during drug development. -
Drug Impurity
Propofol Impurity 1 is a known impurity of the anesthetic agent Propofol, primarily used in the study of drug formulation purity and stability. Its characterization is essential for ensuring the quality of Propofol in pharmaceutical applications. Research involving this impurity can provide insights into the metabolization and potential effects associated with Propofol administration, contributing to safer therapeutic practices. -
Drug Impurity
3,5-Dimethylbenzonitrile serves as a drug impurity often encountered during synthetic processes. This compound is important for quality control in pharmaceutical research, aiding in the identification and quantification of unintended byproducts. Its presence is relevant in the assessment of drug safety and efficacy, making it a valuable reagent in analytical chemistry and toxicology studies. -
Drug Impurity
Rivaroxaban impurity 43 is a specific impurity associated with the anticoagulant Rivaroxaban. This chemical reagent is primarily utilized in the characterization and analysis of Rivaroxaban formulations to ensure quality control and compliance with pharmaceutical standards. Its presence can impact the pharmacokinetics and safety profile of the drug, making it an essential component in drug formulation research and development. -
Drug Impurity
Olmesartan impurity 13 is a specific impurity associated with the angiotensin II receptor blocker, Olmesartan. This compound is important for analytical and quality control applications in pharmaceutical research, particularly in ensuring the purity and safety of Olmesartan formulations. Its presence can impact the efficacy and safety profile of the drug, making it a relevant focus in pharmacological studies and drug development processes. -
Drug Impurity
Amodiaquine impurity 1 is a drug impurity associated with Amodiaquine, a chloroquine derivative primarily utilized in antimalarial therapy. This impurity may impact the pharmacodynamics and stability of the parent compound, making it crucial for analytical and quality control studies in pharmaceutical research. Its characterization is essential for understanding drug formulation and ensuring compliance with regulatory standards. -
Drug Impurity
Nintedanib Impurity 6 is a drug impurity associated with the pharmaceutical compound Nintedanib, which acts as a multi-tyrosine kinase inhibitor. Its primary mechanism involves inhibiting kinases such as VEGFR, PDGFR, and FGFR, which are implicated in angiogenesis and tumor growth. This impurity may be used for analytical purposes in the development and quality control of Nintedanib, ensuring the integrity and safety of pharmaceutical formulations. Research applications include purity assessment and stability studies within pharmaceutical chemistry.
